GSK earnings

Quote

anonymous

Guest
GSK will announce earnings next week. Usually this is the time of year when layoffs are announced. What happened to all you people who put posts on cafe pharma claiming “2020 will be the year for major cuts”. All you doom and gloom people are silent now.
 






anonymous said:
GSK will announce earnings next week. Usually this is the time of year when layoffs are announced. What happened to all you people who put posts on cafe pharma claiming “2020 will be the year for major cuts”. All you doom and gloom people are silent now.
Click to expand...
Thanksgiving, that’s when the changes are announced. Stock in the toilet, no access, won’t be long!
 












Someone tell the CEO that the job is to increase the stock price. GSK shares are down over -20% from $43 to $34 since she took over in early 2017. DOW 30 Industrials are up over +30% from the same time.
 






$34 is embarrassing. Just shows what analysts think of Gsk. Late to the party in established therapeutic markets. At this price expect a takeover or just an outright buy.
 






anonymous said:
$34 is embarrassing. Just shows what analysts think of Gsk. Late to the party in established therapeutic markets. At this price expect a takeover or just an outright buy.
Click to expand...

AZN has certainly fared better the last few years. Their CEO has built a powerhouse oncology business in just a few years and the growth and stock price reflect it.
 






Another failing leader at GSK-Lady Wamsley! We don’t care about your accolades! When is this socialistic company going to appoint someone from the US. Most employees don’t even invest in our own stock!
 






Pharmaceuticals and Biologics ain't makeup! It ain't over the counter products. It is a unique industry that has a completely different set of challenges and barriers. We all know why she was appointed. Just look at our executive leadership team. A lot of estrogen. And while I have no problem with that in theory, I do have problem with placing incompetent people in leadership roles. This organization has done it repeatedly and at every level. The sad part about all of this is that $hit rolls down hill. Guess who's at the bottom of the hill? We will pay the price for poor leadership and the cost will be peoples jobs. So very very shameful and sad. Thanks Emma!
 






anonymous said:
Pharmaceuticals and Biologics ain't makeup! It ain't over the counter products. It is a unique industry that has a completely different set of challenges and barriers. We all know why she was appointed. Just look at our executive leadership team. A lot of estrogen. And while I have no problem with that in theory, I do have problem with placing incompetent people in leadership roles. This organization has done it repeatedly and at every level. The sad part about all of this is that $hit rolls down hill. Guess who's at the bottom of the hill? We will pay the price for poor leadership and the cost will be peoples jobs. So very very shameful and sad. Thanks Emma!
Click to expand...

Clearly this company is mismanaged. The stock has traded sideways now since 2009. Scandal after scandal. We now live in a world where what is wrong is right-write, what is up is down and what is immoral is the moral platitude. Since her grand entrance has she done anything fantastic? Stock is tanking, she has 3 pillars to grow GSK, one of them being trust. Ask yourself how solid is the foundation of that. I wouldn't expect anything to turn around anytime soon.
 






















































Emma's environmental pledge, aka Panic Mode, aka grasping at straws. This is what happens when you promote someone based on Race or gender, not on ability. The outcome you are witnessing here is a direct result of this company doing just that for a very long time. Stock trading south of $37.00, when was the last time it saw $50? Time is not on managements side. Stop calling them "leaders", there isn't a leader amongst any of them! Funny how they call themselves "Leadership" Arrogance is not leadership.
 






When will GSK finally decide so have an committed focus and take some risk in R&D instead of reorganizing every 3 to 5 years? This type of work is not like a company that makes chips or widgets that can squeeze out a greater profit by squeezing the staff. New, novel products require investment or money to buy someone else as does Pfizer. I am not impress with the current head of R&D that he can turn it around. Smart guy. Clever guy. But can he deliver? His history suggests no. Stock has been in the gutter for more almost 2 decades now since the merger between GW and GSK. Something needs to change big time. My suggestion, make a US based company, not UK, and let them rock and roll.
 












Top Bottom
Back
Quote